8 terminated. 8 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Terminated 8 |
| Phase 2 | 1 | Terminated 1 |
Follow Dyssomnias: new trials by email Literature Review of Dyssomnias trials Research Report on Dyssomnias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1 JZP441, Matching Placebo - Narcolepsy | Phase 1 | Terminated | Jazz Pharmaceuticals | 6 | 2025-05-13 | 2026-04-06 |
| Study of MK-6552 in Participants With Narcolepsy Type 1 (MK-6552-004) MK-6552, Placebo - Narcolepsy | Phase 1 | Terminated | Merck Sharp & Dohme LLC | 9 | 2024-01-24 | 2026-04-14 |
| Metabolic Effects of Metformin Therapy in Obstructive Sleep Apnea Metformin + PAP, Placebo oral capsule + PAP - Sleep Apnea, Obstructive | Phase 1 / Phase 2 | Terminated | Pennington Biomedical Research Center | 16 | 2021-01-28 | 2023-01-19 |
| Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human Volunteers GATE-101 - Major Depressive Disorder, Excessive Sleepiness | Phase 1 | Terminated | Syndeio Biosciences, Inc | 18 | 2020-10-26 | 2022-08-03 |
| The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females Zolpidem, ECG - Prostatic Neoplasms | Phase 1 | Terminated | National Cancer Institute (NCI) | 12 | 2019-01-22 | 2026-06-26 |
| Cycloserine in the Treatment of Sleep Apnea Cycloserine, Placebo - Sleep Apnea Syndromes | Phase 1 | Terminated | University of Manitoba | 18 | 2015-09-01 | 2019-09-17 |
| Sleep Effectiveness and Insulin and Glucose Homeostasis eszopiclone - Diabetes, Prediabetic | Phase 1 | Terminated | Beth Israel Deaconess Medical Center | 20 | 2012-10-01 | 2019-12-19 |
| A Study to Evaluate the Pharmacokinetics of LY2624803 in Subjects With Hepatic Impairment LY2624803 - Insomnia | Phase 1 | Terminated | Eli Lilly and Company | 2010-11-01 | 2011-06-03 |
Sleep Initiation and Maintenance Disorders (3) · Narcolepsy (2) · Depressive Disorder, Major (1) · Diabetes Mellitus (1) · Disorders of Excessive Somnolence (1) · Glucose Intolerance (1) · Prediabetic State (1) · Prostatic Neoplasms (1) · Sleep Apnea Syndromes (1) · Sleep Apnea, Obstructive (1)
Nervous System Diseases (8) · Sleep Disorders, Intrinsic (8) · Sleep Wake Disorders (8) · Mental Disorders (6) · Apnea (2) · Disorders of Excessive Somnolence (2) · Respiration Disorders (2) · Respiratory Tract Diseases (2) · Depressive Disorder (1) · Endocrine System Diseases (1) · Genital Diseases (1) · Genital Diseases, Male (1) · Genital Neoplasms, Male (1) · Glucose Metabolism Disorders (1)
Cycloserine (1) · Electrocardiography (1) · Eszopiclone (1) · Metformin (1) · Sugars (1) · Zolpidem (1)
Beth Israel Deaconess Medical Center (1) · Eli Lilly and Company (1) · Jazz Pharmaceuticals (1) · Merck Sharp & Dohme LLC (1) · National Cancer Institute (NCI) (1) · Pennington Biomedical Research Center (1) · Syndeio Biosciences, Inc (1) · University of Manitoba (1)
United States (6) · Canada (1) · Germany (1) · Hungary (1) · Russia (1)
Magdy K Younes, Md, PhD (1) · Melanie Pogach, MD (1) · Prachi Singh, PhD (1) · Ronald M Burch, MD, PhD (1) · William D Figg, Pharm.D. (1)
P30DK072476 (1)